ReviewJapanese journal of radiology2025
Overview of MRI findings in progressive multifocal leukoencephalopathy.
Review in Japanese journal of radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Progressive multifocal leukoencephalopathy in an untreated chronic lymphocytic leukemia patient: Case report and review of the literature.Radiology case reports · 2026Article
- Progressive Multifocal Leukoencephalopathy or Lymphoma? A Massive Unilateral Hemispheric Mimicker in a Patient Undergoing Lymphoma Treatment.Reports (MDPI) · 2026Article
- Progressive multifocal leukoencephalopathy - a diagnostic guide for the clinical neurologist.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the central nervous system caused by JC virus (JCV) infection. PML affects patients with various underlying conditions, such as HIV/AIDS, hematological malignancies, organ transplants, autoimmune diseases, or multiple sclerosis particularly those receiving disease-modifying therapies. MRI plays a crucial role in diagnosis, demonstrating characteristic findings across multiple sequences, including T2-weighted imaging (T2WI)/fluid-attenuated inversion recovery (FLAIR), T1-weighted imaging (T1WI), diffusion-weighted imaging (DWI), and susceptibility-weighted imaging (SWI). Early stage markers first appear as a cluster of punctate high-signal areas in T2WI (the "punctate pattern") and later develop into a distribution of oval-shaped lesions of varying sizes, commonly referred to as the "milky way appearance." Lesions typically show T2WI/FLAIR hyperintensity, T1WI hypointensity, and DWI hyperintensity. Recent findings highlight the significance of SWI hypointensity as a potential early marker. The prognosis varies significantly depending on the underlying condition and timing of diagnosis, with mortality rates ranging from 20 to 90%. Early detection, particularly in asymptomatic stages, significantly improves survival rates, emphasizing the importance of regular MRI screening in high-risk patients. Diagnostic challenges include low JCV DNA levels in cerebrospinal fluid (CSF), particularly in early stages and drug-associated cases, necessitating ultrasensitive PCR testing. This review provides an overview of PML's imaging characteristics, with particular emphasis on early diagnostic features using MRI, with a detailed understanding of PML's imaging characteristics across various stages and clinical subtypes, aiming to improve patient outcomes through early detection and intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.